Function of the GABAergic System in Diabetic Encephalopathy

Zhou, Hongli; Rao, Zhili; Zuo, Zhuang; Zhou, Jiyin

doi:10.1007/s10571-022-01214-7

Cited by 5 publications

(2 citation statements)

References 143 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our observation of the reduced [ 18 F]flumazenil measure of GABA A receptors in the cortex and hippocampus of aged ZDF rats compared to SD rats is in line with the known alterations of GABA A receptors in the brain of ZDF rat models [4]. Given the important role of the GABAergic system in diabetic cognitive dysfunction, blood sugar control and energy homeostasis [51], the GABAergic system has been an important drug target for T2DM. Therefore, [ 18 F]flumazenil might be useful in further investigation and monitoring of therapeutics targeting GABAergic impairment in T2DM.…”

Section: Discussionsupporting

confidence: 86%

Reduced SV2A and GABA_Areceptor levels in the brains of type 2 diabetic rats revealed by [¹⁸F]SDM-8 and [¹⁸F]flumazenil PET

Kong,

Xie,

Wang

et al. 2023

Preprint

View full text Add to dashboard Cite

PurposeType 2 diabetes mellitus (T2DM) is associated with a greater risk of Alzheimer’s disease. Synaptic impairment and protein aggregates have been reported in the brains of T2DM models. Here, we assessed whether neurodegenerative changes in synaptic vesicle 2A (SV2A), γ;-aminobutyric acid type A (GABAA) receptor, amyloid-β, tau and receptor for advanced glycosylation end product (RAGE) can be detected in vivo in T2DM rats.MethodsPositron emission tomography (PET) using [18F]SDM-8 (SV2A), [18F]flumazenil (GABAAreceptor), [18F]florbetapir (amyloid-β), [18F]PM-PBB3 (tau), and [18F]FPS-ZM1 (RAGE) was carried out in 12-month-old diabetic Zucker diabetic fatty (ZDF) and Sprague□Dawley (SD) rats. Proteomic profiling and pathway analysis of the hippocampus of ZDF and SD rats were performed.ResultsReduced cortical [18F]SDM-8 and cortical and hippocampal [18F]flumazenil uptake were observed in 12-month-old ZDF rats compared to SD rats. [18F]florbetapir and [18F]PM-PBB3 uptake were comparable in the brains of 12-month-old ZDF rats and SD rats.ConclusionThe findings provide in vivo evidence for regional reductions in SV2A and GABAAreceptor levels in the brains of aged T2DM ZDF rats.

show abstract

Section: Discussionsupporting

confidence: 86%

Reduced SV2A and GABA_Areceptor levels in the brains of type 2 diabetic rats revealed by [¹⁸F]SDM-8 and [¹⁸F]flumazenil PET

Kong,

Xie,

Wang

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…These properties of Best1-channel lead to the hypothesis that distorted regulation of intracellular Ca 2+ signaling [54,55] and/or pH homeostasis [51] may underlie the Best1 mutation-related retinopathies (for recent review, [25]). Moreover, diabetic retinopathy is accompanied by a reduction in GABA release in the retina, leading to hyperexcitation (for review, [56]), but the role of possible Best1-mediated GABA release in the retina needs further investigation. [23]).…”

Section: Volume-regulated Anionic Channels-bestrophin1mentioning

confidence: 99%

GABA Release from Astrocytes in Health and Disease

Kilb

Kirischuk

2022

IJMS

View full text Add to dashboard Cite

Astrocytes are the most abundant glial cells in the central nervous system (CNS) mediating a variety of homeostatic functions, such as spatial K+ buffering or neurotransmitter reuptake. In addition, astrocytes are capable of releasing several biologically active substances, including glutamate and GABA. Astrocyte-mediated GABA release has been a matter of debate because the expression level of the main GABA synthesizing enzyme glutamate decarboxylase is quite low in astrocytes, suggesting that low intracellular GABA concentration ([GABA]i) might be insufficient to support a non-vesicular GABA release. However, recent studies demonstrated that, at least in some regions of the CNS, [GABA]i in astrocytes might reach several millimoles both under physiological and especially pathophysiological conditions, thereby enabling GABA release from astrocytes via GABA-permeable anion channels and/or via GABA transporters operating in reverse mode. In this review, we summarize experimental data supporting both forms of GABA release from astrocytes in health and disease, paying special attention to possible feedback mechanisms that might govern the fine-tuning of astrocytic GABA release and, in turn, the tonic GABAA receptor-mediated inhibition in the CNS.

show abstract

Reduced SV2A and GABAA receptor levels in the brains of type 2 diabetic rats revealed by [18F]SDM-8 and [18F]flumazenil PET

Kong,

Cao,

Xie

et al. 2024

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

Function of the GABAergic System in Diabetic Encephalopathy

Cited by 5 publications

References 143 publications

Reduced SV2A and GABA_Areceptor levels in the brains of type 2 diabetic rats revealed by [¹⁸F]SDM-8 and [¹⁸F]flumazenil PET

Reduced SV2A and GABA_Areceptor levels in the brains of type 2 diabetic rats revealed by [¹⁸F]SDM-8 and [¹⁸F]flumazenil PET

GABA Release from Astrocytes in Health and Disease

Reduced SV2A and GABAA receptor levels in the brains of type 2 diabetic rats revealed by [18F]SDM-8 and [18F]flumazenil PET

Contact Info

Product

Resources

About

Function of the GABAergic System in Diabetic Encephalopathy

Cited by 5 publications

References 143 publications

Reduced SV2A and GABAAreceptor levels in the brains of type 2 diabetic rats revealed by [18F]SDM-8 and [18F]flumazenil PET

Reduced SV2A and GABAAreceptor levels in the brains of type 2 diabetic rats revealed by [18F]SDM-8 and [18F]flumazenil PET

GABA Release from Astrocytes in Health and Disease

Reduced SV2A and GABAA receptor levels in the brains of type 2 diabetic rats revealed by [18F]SDM-8 and [18F]flumazenil PET

Contact Info

Product

Resources

About

Reduced SV2A and GABA_Areceptor levels in the brains of type 2 diabetic rats revealed by [¹⁸F]SDM-8 and [¹⁸F]flumazenil PET

Reduced SV2A and GABA_Areceptor levels in the brains of type 2 diabetic rats revealed by [¹⁸F]SDM-8 and [¹⁸F]flumazenil PET